• Hector Fellows

    Distinguished researchers in STEM fields.

Prof. Dr. Dr. h.c. mult. Eberhart Zrenner

Institute for Ophthalmic Research of the University Hospital, Eberhard Karls Universität Tübingen

Hector Fellow since 2012

Eberhart Zrenner is Senior Professor of Ophthalmology at the Werner Reichardt Centre for Integrative Neuroscience and Founding Director of the Institute for Ophthalmic Research of the University of Tübingen.

He is a worldwide acknowledged expert for retinal degenerative diseases in particular in the field of aetiology and therapy development. He belongs to the pioneers in the development of sub-retinal electronic chips aiming at functional restoration of vision. With the help of these chips, which are now approved as medical devices and are produced by the Retina Implant AG cofounded by Zrenner, blind test persons were able to recognize objects and read words.

For his work, he was granted the Ludwig von Sallmann Prize und den Karl Heinz Beckurts Prize. He is a member of the German National Academy of Sciences (Leopoldina) and the Heidelberg Academy of Sciences and Humanities. Until 2005, he was senator of the Max Planck Society and until 2009 member of the German Council of Science and Humanities, as well as the Council of Health Research.

Research fields

  • Degenerative diseases of the retina
  • Ocular toxicology and clinical electrophysiology
  • Optoelectronical retinal implants

Video

Enable Blind People to see again - Retinal Implants with integrated microelectrodes make it possible

Eberhart Zrenner and his team are developing novel micro-electrodes based on high-tech materials for the spatial and temporal high-resolution electrical stimulation of neuronal tissue. In the therapy of patients suffering from hereditary retinal degeneration, these will contribute to an even clearer improvement in visual performance.

See here in the short film "Enable blind people to see again" what relevance Zrenner's research has for the cooperation between medicine and technology as well as the therapy of patients suffering from hereditary retinal degeneration.